ARWR - Arrowhead finishes enrollment in phase 2b trial of ARO-ANG3 for mixed dyslipidemia

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reached full planned enrollment of more than 180 people in the phase 2b trial of ARO-ANG3 to treat patients with mixed dyslipidemia. The study, dubbed ARCHES-2, is expected to be completed around the end 2022 and the company intends to report topline data in H1 2023. Dyslipidemia is an abnormal amount of lipids in the blood. "The ARCHES-2 clinical study will evaluate safety and efficacy and identify an optimal dose and dosing regimen of ARO-ANG3 to be assessed in future late-stage clinical studies," said Javier San Martin, chief medical officer at Arrowhead. ARWR -3.68% premarket to $40

For further details see:

Arrowhead finishes enrollment in phase 2b trial of ARO-ANG3 for mixed dyslipidemia